A catalyst made in situ from the (cyclooctadiene)iridium chloride dimer, [Ir(COD)Cl] 2 , and the monodentate phosphoramidite ligand ( S )‐PipPhos was used in the enantioselective hydrogenation of 2‐ and 2,6‐substituted quinoxalines. In the presence of piperidine hydrochloride as additive full conversions and enantioselectivities of up to 96% are obtained.
No takes yet. Share an insight, caveat, or question.
Mršić et al. (2009) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: